Cardiovascular Actions of the Furoxan CAS 1609, a Novel Nitric Oxide Donor

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1995 Apr 1

PMID 7599929

Citations 12

Authors

H Bohn

J Brendel

P A Martorana

K Schonafinger

Affiliations

Soon will be listed here.

Abstract

1. This study examines the cardiovascular effects of CAS 1609 (4-hydroxymethyl-furoxan-3-carboxamide) in vitro as well as in vivo in various animal models. 2. CAS 1609 relaxed guinea-pig pulmonary artery strips without endothelium with IC50-values of 0.9 microM (phenylephrine contracted) and 15 microM (KCl-depolarized). This effect was inhibited by oxyhaemoglobin. In these arteries CAS 1609 significantly increased (+192%) guanosine 3':5'-cyclic monophosphate levels, which indicates that the compound acts as a donor of nitric oxide (NO). 3. In the anaesthetized pig, CAS 1609 (0.3-1.0 mg kg-1, i.d.) significantly lowered blood pressure and left ventricular end-diastolic pressure. Left ventricular contractility was slightly reduced and heart rate remained almost unchanged. 4. In anaesthetized dogs, i.v. or i.d. administration of CAS 1609 (0.3-3.0 mg kg-1) decreased, in a dose-related fashion, preload and afterload of the heart, cardiac output, left ventricular work and myocardial oxygen consumption. This haemodynamic profile is similar to that of known NO-donors. 5. In anaesthetized dogs with acute heart failure due to intracoronary injection of microspheres, CAS 1609 (0.3 mg kg-1, i.v.) improved the haemodynamic condition and reduced mortality by 80%. 6. In conscious dogs, oral treatment with a dose of 0.5 mg kg-1 given twice daily at 07 h 00 min and 19 h 00 min (each dose had a duration of action > or = 12 h) for 5 days showed no signs of tolerance to the haemodynamic effects of the drug. 7. All these data indicate that CAS 1609 is a potent, long-lasting orally active donor of NO, devoid of tolerance development.

Citing Articles

Exploring the Anticancer Potential of NO-Donor Oxadiazole Assemblies Against Malignant Pleural Mesothelioma.

Stebletsova I, Larin A, Matnurov E, Ananyev I, Babak M, Fershtat L Pharmaceutics. 2025; 17(2).

PMID: 40006597 PMC: 11859074. DOI: 10.3390/pharmaceutics17020230.

Significance of Chalcone Scaffolds in Medicinal Chemistry.

Mazumder R, Ichudaule , Ghosh A, Deb S, Ghosh R Top Curr Chem (Cham). 2024; 382(3):22.

PMID: 38937401 DOI: 10.1007/s41061-024-00468-7.

Proteomics Studies Suggest That Nitric Oxide Donor Furoxans Inhibit In Vitro Vascular Smooth Muscle Cell Proliferation by Nitric Oxide-Independent Mechanisms.

Lazzarato L, Bianchi L, Andolfo A, Granata A, Lombardi M, Sinelli M Molecules. 2023; 28(15).

PMID: 37570694 PMC: 10420201. DOI: 10.3390/molecules28155724.

Recent Advances in the Synthesis and Biomedical Applications of Heterocyclic NO-Donors.

Fershtat L, Zhilin E Molecules. 2021; 26(18).

PMID: 34577175 PMC: 8470015. DOI: 10.3390/molecules26185705.

Controlled Delivery of Nitric Oxide for Cancer Therapy.

Alimoradi H, Greish K, Gamble A, Giles G Pharm Nanotechnol. 2019; 7(4):279-303.

PMID: 31595847 PMC: 6967185. DOI: 10.2174/2211738507666190429111306.

References

Langer S, Trendelenburg U . The effect of a saturable uptake mechanism on the slopes of dose-response curves for sympathomimetic amines and on the shifts of dose-response curves produced by a competitive antagonist. J Pharmacol Exp Ther. 1969; 167(1):117-42. View

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

FURCHGOTT R . Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983; 53(5):557-73. DOI: 10.1161/01.res.53.5.557. View

Martin W, Villani G, Jothianandan D, FURCHGOTT R . Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther. 1985; 232(3):708-16. View

Rapoport R, Schwartz K, Murad F . Effect of sodium-potassium pump inhibitors and membrane-depolarizing agents on sodium nitroprusside-induced relaxation and cyclic guanosine monophosphate accumulation in rat aorta. Circ Res. 1985; 57(1):164-70. DOI: 10.1161/01.res.57.1.164. View

Leitold M, Laufen H, Yeates R . [Comparative pharmacology of glycerol-1-nitrate and glyceryl trinitrate in various species]. Arzneimittelforschung. 1986; 36(5):814-21. View

Bohn H, Rosenstein B . Technical notes on chronic fluid-filled catheters and renal artery constrictors for testing hemodynamic drug effects in conscious hypertensive dogs. J Pharmacol Methods. 1986; 16(3):227-38. DOI: 10.1016/0160-5402(86)90044-6. View

ODonnell S, Barnett C . pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets. Br J Pharmacol. 1988; 94(2):437-42. PMC: 1853981. DOI: 10.1111/j.1476-5381.1988.tb11545.x. View

Gillespie J, Sheng H . Influence of haemoglobin and erythrocytes on the effects of EDRF, a smooth muscle inhibitory factor, and nitric oxide on vascular and non-vascular smooth muscle. Br J Pharmacol. 1988; 95(4):1151-6. PMC: 1854279. DOI: 10.1111/j.1476-5381.1988.tb11750.x. View

10.

Chung S, Fung H . Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther. 1990; 253(2):614-9. View

11.

Silber S . Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate. Eur J Clin Pharmacol. 1990; 38 Suppl 1:S35-51. DOI: 10.1007/BF01417564. View

12.

Bohn H, Schonafinger K . Oxygen and oxidation promote the release of nitric oxide from sydnonimines. J Cardiovasc Pharmacol. 1989; 14 Suppl 11:S6-12. View

13.

Moncada S, Palmer R, Higgs E . Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43(2):109-42. View

14.

Bohn H, Beyerle R, Martorana P, Schonafinger K . CAS 936, a novel syndnonimine with direct vasodilating and nitric oxide-donating properties: effects on isolated blood vessels. J Cardiovasc Pharmacol. 1991; 18(4):522-7. DOI: 10.1097/00005344-199110000-00007. View

15.

Ghigo D, Heller R, Calvino R, Alessio P, Fruttero R, Gasco A . Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. Biochem Pharmacol. 1992; 43(6):1281-8. DOI: 10.1016/0006-2952(92)90504-c. View

16.

Bennett B, McDonald B, St James M . Hepatic cytochrome P-450-mediated activation of rat aortic guanylyl cyclase by glyceryl trinitrate. J Pharmacol Exp Ther. 1992; 261(2):716-23. View

17.

Calvino R, Fruttero R, Ghigo D, Bosia A, Pescarmona G, Gasco A . 4-Methyl-3-(arylsulfonyl)furoxans: a new class of potent inhibitors of platelet aggregation. J Med Chem. 1992; 35(17):3296-300. DOI: 10.1021/jm00095a028. View

18.

Feelisch M, Schonafinger K, Noack E . Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol. 1992; 44(6):1149-57. DOI: 10.1016/0006-2952(92)90379-w. View

19.

Bohn H, Martorana P, Schonafinger K . Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs. Eur J Pharmacol. 1992; 220(1):71-8. DOI: 10.1016/0014-2999(92)90013-t. View

20.

Moncada S, Higgs A . The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329(27):2002-12. DOI: 10.1056/NEJM199312303292706. View